🍪 CompoundTalk uses cookies to improve your experience, analyze traffic, and personalize content. By continuing to use this site, you agree to our Cookie Policy.
Evidence-based GLP-1 & peptide discussion since 2023
ForumsLab Results & BiomarkersMy 12-month lab diary — every panel from baseline to maintenance

My 12-month lab diary — every panel from baseline to maintenance

quinn_sf Tue, May 19, 2026 at 10:13 AM 15 replies 555 viewsPage 1 of 3
quinn_sf
Member
489
2,123
Jun 2024
San Francisco, CA
May 19, 2026 at 10:13 AM#1

I am eight weeks into deliberately reducing rather than stopping, and the appetite change came back faster than the weight did.

What I am after is whether extending the interval works as well as reducing the dose, since they are not the same intervention pharmacologically.

I would rather have one careful answer than five confident ones.

15 18tane_welly, Dr.PathRoch, mona_PHX and 12 others
Reply Quote Save Share Report
LabKate
Senior Member
2,678
11,234
Jan 2024
Oregon
May 19, 2026 at 11:17 AM#2

Taking the question as asked, rather than the general version of it. Extending the interval and reducing the dose are pharmacologically different. Reducing the dose lowers the whole exposure curve evenly; extending the interval keeps the peak and drops the trough. Since the appetite effect tracks the trough, interval extension tends to give you good days and bad days rather than a uniformly smaller effect, which most people find harder to live with.

16 19laura_annarbor, JenMemphis, pat_auckland and 13 others
Reply Quote Save Share Report
LindaRN_retired
Member
189
890
Dec 2024
Sarasota, FL
May 19, 2026 at 12:21 PM#3
LabKate said:
Extending the interval and reducing the dose are pharmacologically different.

Agreed, and reference ranges are laboratory-specific. Comparing your number to somebody else's range, or to a screenshot from another country, is how people convince themselves something is wrong.

That is the short version; the long version is somebody else's post.

17 20amsterdam_pete, LondonLisa, mike_nyc and 14 others
Reply Quote Save Share Report

Sigma-Aldrich — Research-Grade Standards

Certified reference materials, analytical reagents, and research-grade standards for peptide verification. Trusted by laboratories worldwide.

Shop Reference Standards
tom_AK
New Member
28
112
Jan 2026
Anchorage, AK
May 19, 2026 at 1:25 PM#4
quinn_sf said:
I am eight weeks into deliberately reducing rather than stopping, and the appetite change came back faster than the weight did.

This matches mine closely enough to be worth saying so. STEP 4 is the study that answers this and it is blunt. Participants who continued kept losing; participants switched to placebo regained about two thirds of what they had lost within a year, and the metabolic improvements faded with the weight. That is the same pattern as every other chronic-disease medication ever withdrawn, and it is an argument about the condition rather than about the drug.

18 21jennifer_SEA, tyler_CSCS, VanRx_Mike and 15 others
Reply Quote Save Share Report
JenPlateau
Member
234
890
Nov 2024
Missouri
May 19, 2026 at 7:30 PM#5

Adding the clinical framing, because it changes how the question reads.

Epigenetic implications of GLP-1 therapy and maintenance dosing: emerging evidence suggests that sustained weight loss and metabolic improvement may produce epigenetic changes (DNA methylation, histone modification) that persist beyond drug discontinuation[1].

This is speculative but fascinating: could long-term GLP-1 agonist treatment "reprogram" metabolic gene expression? If so, it would explain why some patients maintain weight loss better than others after discontinuation.

More research needed, but the concept of pharmacologically-induced epigenetic remodeling is intellectually exciting.

References:
[1] Ling C, et al. Diabetologia. 2023;66(6):1078-1093.
19 22sarah_nash92, FitDadDave, RunnerRach and 16 others
Reply Quote Save Share Report

Similar Threads

Optimal lab testing frequency on GLP-1 — evidence-based schedule5 replies
A1C from 7.2 to 5.1 — my bloodwork transformation19 replies
Thyroid function monitoring on GLP-1 — TSH and free T4 trends3 replies
Lipid panel improvements mega-thread — share your numbers19 replies
Liver enzymes trending down on GLP-1 — ALT/AST normalization17 replies
ForumsNewTrendingMembersAccount

Log In

Forgot password?
No account? Register